BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004;15:1517-1526. [PMID: 15367413 DOI: 10.1093/annonc/mdh395] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004;9:518-27. [PMID: 15477636 DOI: 10.1634/theoncologist.9-5-518] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
2 Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat. 2005;92:1-9. [PMID: 15980985 DOI: 10.1007/s10549-005-0322-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
3 Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017;6:CD003374. [PMID: 28643430 DOI: 10.1002/14651858.CD003374.pub4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
4 Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J. Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2004;:CD003367. [PMID: 15495049 DOI: 10.1002/14651858.CD003367.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010;119:621-31. [DOI: 10.1007/s10549-009-0630-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
6 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
7 Zhu T, Liu CL, Zhang YF, Liu YH, Xu FP, Zu J, Zhang GC, Li XR, Liao N, Wang K. A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat 2016;156:117-24. [PMID: 26936755 DOI: 10.1007/s10549-016-3735-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
8 Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Théberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst 2011;103:178-231. [PMID: 21217081 DOI: 10.1093/jnci/djq508] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
9 Adamowicz K, Jassem J, Katz A, Saad ED. Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treat Rev 2012;38:554-8. [PMID: 21807465 DOI: 10.1016/j.ctrv.2011.07.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
10 Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther 2016;9:5073-80. [PMID: 27574448 DOI: 10.2147/OTT.S106574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
11 Zhu T, Xu F, Zhang L, Zhang Y, Yang C, Cheng M, Chen F, Wang K. Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy. Oncotarget 2017;8:101087-94. [PMID: 29254147 DOI: 10.18632/oncotarget.19686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Reed E, Kössler I, Hawthorn J. Quality of life assessments in advanced breast cancer: should there be more consistency?: Quality of life assessment in advanced breast cancer. European Journal of Cancer Care 2012;21:565-80. [DOI: 10.1111/j.1365-2354.2012.01370.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
13 Segawa T, Kamoto T, Kinoshita H, Kunishima Y, Yoshimura K, Ito A, Takahashi T, Higashi S, Nakamura E, Nishiyama H, Ito N, Yamamoto S, Habuchi T, Ogawa O. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. Int J Clin Oncol 2005;10:333-7. [DOI: 10.1007/s10147-005-0513-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
14 Stathopoulos GP, Tsavdaridis D, Malamos NA, Rigatos SK, Kosmas C, Pergantas N, Stathopoulos JG, Xynotroulas J. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol 2005;56:487-91. [DOI: 10.1007/s00280-005-1006-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
15 Freedman O, Amir E, Zimmermann C, Clemons M. Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Support Care Cancer 2011;19:315-22. [PMID: 21203780 DOI: 10.1007/s00520-010-1069-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
16 Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 2008;100:1780-91. [PMID: 19066278 DOI: 10.1093/jnci/djn414] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 6.8] [Reference Citation Analysis]
17 Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218-28. [PMID: 18329278 DOI: 10.1016/j.critrevonc.2008.01.008] [Cited by in Crossref: 150] [Cited by in F6Publishing: 124] [Article Influence: 11.5] [Reference Citation Analysis]
18 Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2012;70:169-76. [PMID: 22669571 DOI: 10.1007/s00280-012-1901-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
19 Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-42. [PMID: 16575015 DOI: 10.1200/JCO.2005.04.0543] [Cited by in Crossref: 320] [Cited by in F6Publishing: 129] [Article Influence: 21.3] [Reference Citation Analysis]
20 Morabito A, Piccirillo MC, Monaco K, Pacilio C, Nuzzo F, Chiodini P, Gallo C, de Matteis A, Perrone F; NCI Naples Breast Cancer Group. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Oncologist 2007;12:1288-98. [PMID: 18055848 DOI: 10.1634/theoncologist.12-11-1288] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol 2010;21:1462-7. [PMID: 20019086 DOI: 10.1093/annonc/mdp551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M. Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01. JCO 2005;23:8322-30. [DOI: 10.1200/jco.2005.01.1817] [Cited by in Crossref: 43] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
23 Kiely BE, Soon YY, Tattersall MH, Stockler MR. How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. JCO 2011;29:456-63. [DOI: 10.1200/jco.2010.30.2174] [Cited by in Crossref: 94] [Cited by in F6Publishing: 28] [Article Influence: 9.4] [Reference Citation Analysis]
24 Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. Anti-Cancer Drugs 2010;21:785-9. [DOI: 10.1097/cad.0b013e32833d5ec0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Petrelli F, Barni S, Bregni G, de Braud F, Di Cosimo S. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. Breast Cancer Res Treat 2016;160:425-37. [PMID: 27770282 DOI: 10.1007/s10549-016-4025-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
26 Kus T, Aktas G, Kalender ME, Sevinc A, Kul S, Suner A, Ulker E, Camci C. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Support Care Cancer 2016;24:1175-9. [DOI: 10.1007/s00520-015-2898-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
27 Verma S, Clemons M. First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 2007;12:785-97. [PMID: 17673610 DOI: 10.1634/theoncologist.12-7-785] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
28 Melichar B, Hyspler R, Dragounová E, Dvorák J, Kalábová H, Tichá A. Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum. BMC Cancer 2007;7:155. [PMID: 17688683 DOI: 10.1186/1471-2407-7-155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
29 Zheng R, Han S, Duan C, Chen K, You Z, Jia J, Lin S, Liang L, Liu A, Long H, Wang S. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials. Medicine (Baltimore) 2015;94:e803. [PMID: 25929935 DOI: 10.1097/MD.0000000000000803] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
30 Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006;23:147-60. [PMID: 16720915 DOI: 10.1385/MO:23:2:147] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
31 Greenberg S, Rugo HS. Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer. Clinical Breast Cancer 2010;10:S20-9. [DOI: 10.3816/cbc.2010.s.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007. European Journal of Cancer 2008;44:2218-25. [DOI: 10.1016/j.ejca.2008.07.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
33 Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL). Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol 2018;19:e459-69. [PMID: 30191850 DOI: 10.1016/S1470-2045(18)30418-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
34 Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561-574. [PMID: 20808300 DOI: 10.1038/nrclinonc.2010.122] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
35 Maniadakis N, Dafni U, Fragoulakis V, Grimani I, Galani E, Fragkoulidi A, Fountzilas G. Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Annals of Oncology 2009;20:278-85. [DOI: 10.1093/annonc/mdn634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
36 Vernieri C, Milano M, Mennitto A, Maggi C, Ferrari B, Rinaldi L, Mennitto R, Stefanetti C, Re B, Mariani G, Bianchi G, Capri G, de Braud F. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. Breast Cancer Res Treat 2017;165:365-73. [PMID: 28616768 DOI: 10.1007/s10549-017-4336-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2015;152:95-117. [PMID: 26044370 DOI: 10.1007/s10549-015-3453-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
38 Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 2010;17:148-58. [PMID: 19417586 DOI: 10.1097/MJT.0b013e3181a3e50b] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
39 Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 2005;252:1459-64. [PMID: 16284715 DOI: 10.1007/s00415-005-0887-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
40 Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009;115:87-99. [DOI: 10.1007/s10549-008-0047-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
41 Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart M, Zardavas D, Nagele E, Bjelic-radisic V, Cardoso F, Sprangers MAG, Velikova G, Bottomley A. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. The Lancet Oncology 2016;17:e294-304. [DOI: 10.1016/s1470-2045(16)30099-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
42 Heath EI, Blumenschein GR Jr, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 2011;68:703-12. [PMID: 21140147 DOI: 10.1007/s00280-010-1536-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
43 Recinos VR, Bekelis K, Ziegler SG, Vick D, Hertig S, Tyler BM, Li KW, Kosztowski T, Legnani FG, Brem H, Olivi A. Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J Neurooncol 2010;97:1-10. [DOI: 10.1007/s11060-009-9984-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011;57:468-87. [PMID: 22248721 DOI: 10.1159/000334093] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
45 Chen X, Nie X, Chen C, Wu J, Wu J, Lu J, Shao Z, Shen Z, Shen K. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Annals of Oncology 2010;21:961-7. [DOI: 10.1093/annonc/mdq041] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
46 Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G. Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. Clinical Breast Cancer 2010;10:230-7. [DOI: 10.3816/cbc.2010.n.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]